Venous thromboembolism in patients with COVID-19 and correlation with D-dimers: a single-centre experience

Muhammad Ziaullah Khan, Yousaf Jamal, Benjamin Sutton, Farrukh Rauf

ABSTRACT
Objective To study the frequency of venous thromboembolism in hospitalised patients with COVID-19 and correlation with the D-dimers and thromboprophylaxis.

Design Cross-sectional descriptive study.

Place and duration of study Queen Elizabeth Hospital, Birmingham, between 20 April 2020 and 13 May 2020.

Patients and methods One hundred and seven (n=107) patients of PCR-confirmed COVID-19 pneumonia admitted to Queen Elizabeth Hospital, Birmingham, between 20 April 2020 and 13 May 2020 were included in the study using consecutive sampling. Data were collected using the Excel audit tool and included age, gender, weight, estimated eGFR, D-dimer values on admission, intensive care unit admission, presence of respiratory failure, imaging results for evaluation of venous thromboembolism (VTE) and anticoagulation received on admission. The data were entered in the SPSS (V.17) and were analysed. Data were summarised as means±SD, number or percentage as appropriate. A p value of less than 0.05 was considered significant.

Results The frequency of VTE was found to be 11.2% in patients hospitalised with COVID-19 pneumonia. The mean D-dimers were 3322.24 ng/mL±9603 ng/mL with the values significantly higher for patients with VTE and those requiring intensive care unit admission. All of the seven patients (100%) with D-dimers value above 2000 ng/mL who underwent imaging were found to have VTE.

Conclusion VTE is frequent in patients with COVID-19 pneumonia despite anticoagulation. A higher D-dimers value correlates well with the risk of VTE in these patients and further evaluation of such patients for VTE is necessary especially with D-dimers values above 2000 ng/mL.

OBJECTIVES
To study the frequency of venous thromboembolism in hospitalised patients with COVID-19 and correlation with the D-dimers and thromboprophylaxis.

INTRODUCTION
COVID-19 is a new highly contagious viral illness caused by novel coronavirus (SARS-CoV-2) that emerged in Wuhan City in China in December 2019. Since then, it has spread across the globe, and the outbreak was declared as a Public Health Emergency of International Concern in January 2020.

Most cases are asymptomatic or have mild symptoms including fever, malaise, fatigue, body aches, anosmia and cough. However, in severe illness and particularly those with cytokine storm syndrome, patients can rapidly develop acute respiratory distress syndrome, septic shock, renal failure, hepatitis and coagulopathy including venous thromboembolism (VTE) and disseminated intravascular coagulation.

Patients with severe and critical COVID-19 illness are at increased risk of VTE due to multiple factors including immobilisation, infection, respiratory failure, mechanical ventilation and central venous catheters. Coagulopathy and high D-dimer values have been reported in many studies in these patients with COVID-19, and this phenomenon is associated with increased mortality.
High D-dimer values are often overlooked and considered insignificant being a usual finding in patients with COVID-19. In this cross-sectional study, we evaluated the hospitalised patients with COVID-19 infection for the frequency of VTE and correlated their D-dimers values and anticoagulation status with the risk of thromboembolism.

**METHODOLOGY**

This retrospective cross-sectional study was performed at Queen Elizabeth Hospital, University Hospital Birmingham. Inclusion criteria included adult patients hospitalised with positive swab PCR-detected SARS-CoV2 during the period from 20 April 2020 to 13 May 2020. A total of 107 patients admitted in this period were included in the study by consecutive non-probability sampling. Data were collected through our inpatient management system Prescribing Information & Communication System using an Excel audit tool. The parameters included age, gender, weight, eGFR (estimated glomerular filtration rate), D-dimer values and anticoagulation status on admission, need for intensive care unit (ICU) admission, presence or absence of respiratory failure and VTE during the course of admission.

Patients were classified as receiving optimal, suboptimal or therapeutic anticoagulation by assessing the regimen against the trust guidelines as per following definition:

1. **Optimal anticoagulation**: patients weighing <99 kg on enoxaparin 40 mg daily. If weighing 100–150 kg, then enoxaparin 40 mg twice daily and with weight 100–150 kg enoxaparin 60 mg twice daily in all care settings. Critical care patients with weight <100 kg should have enoxaparin 40 mg twice daily. If eGFR <30 mL/min, then reduce dose by 50%, and if having continuous veno-venous hemodiafiltration on critical care, then 40 mg once daily.

2. **Suboptimal anticoagulation**: patients receiving less than optimal dose adjusted for weight and eGFR.

3. **Therapeutic anticoagulation**: patient started acutely on enoxaparin 1.5 mg/kg with confirmed/suspicion of VTE.

4. **Patient already on direct oral anticoagulants (DOACS)/warfarin for known atrial fibrillation/previous VTE**.

The data was entered in SPSS (V.17) and analysed. Data was summarised as means±SD, number or percentage as appropriate. Fisher’s exact test and t-test were used for the comparison of variables and data as applicable. A p value of less than 0.05 was considered significant.

There was no involvement of the patients or public in the design, conduct, reporting or dissemination plans of our observational study, as it was not required.

**RESULTS**

A total number of 107 patients, 62 men (57.9 %) and 45 women (42.1 %) were evaluated during the duration of the study. The mean age of the patients was 68.9±17.847 years. Ninety-seven patients (90.7 %) had respiratory failure, while 37 patients (34.6 %) required admission to the ICU (tables 1 and 2).

A total of 72 patients (67.3 %) had D-dimers done during the course of their admission, and only 54 patients (50.5 %) had D-dimers done within the first 24 hours (table 2). The mean D-dimer value was 3322.24 ng/mL±9603 ng/mL with a maximum of 72467 ng/mL (table 1). The mean D-dimer value was significantly higher for patients requiring ICU admission. Similarly, values were higher for patients with respiratory failure but did not reach statistical significance (table 3).

Twenty-three patients (21.5 %) underwent imaging including CT pulmonary angiogram (CTPA) (13 patients) and Doppler ultrasound (10 patients) for further evaluation of VTE (table 2). Overall, 12 patients (11.2 %) were found to have VTE on dedicated imaging, 6 patients had PE (50 %) while 6 patients had DVT (50 %) as shown in table 2. The mean D-dimer value of the patients with confirmed VTE was significantly higher than for patients with no VTE on imaging (16218.56±23782 ng/mL, vs 808.78±466.55 ng/mL p value 0.005) (table 3).

All seven patients (100 %) with D-dimers greater than 2000 ng/mL evaluated with dedicated imaging were positive for VTE, while only two (n=11, 18.18 %) patients with D-dimers less than 2000 were positive for VTE on Doppler/CTPA (table 4).

As shown in table 2, overall 104 patients (97.2 %) received any kind of anticoagulation during their admission with 71% receiving optimal anticoagulation. Three patients did not receive anticoagulation because of contraindications including subdural haemorrhage/thrombocytopenia. Five patients (4.7 %) were started on therapeutic anticoagulation on admission that was continued in four of them with subsequent VTE confirmed on imaging. Nine patients (8.4 %) were

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Age, D-dimers and days to diagnosis of VTE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
</tr>
<tr>
<td>Age (years)</td>
<td>107</td>
</tr>
<tr>
<td>Initial D-dimers value (ng/mL)</td>
<td>72</td>
</tr>
<tr>
<td>Days to diagnosis of VTE</td>
<td>12</td>
</tr>
</tbody>
</table>

VTE, venous thromboembolism.
considered to be suboptimally anticoagulated based on their weight and eGFR. Fourteen patients (13.1%) remained on DOACs/oral Warfarin as per their preadmission regimen. Four patients were diagnosed with VTE on admission and placed on therapeutic anticoagulation on admission. The remaining eight patients were diagnosed to have VTE during the course of the admission despite being on optimal anticoagulation. The mean time to diagnosis of VTE was 9.50±11 days. None of the 13 patients on DOACs/warfarin preadmission were diagnosed as having VTE, although only one of them was evaluated by imaging.

**DISCUSSION**

Patients with COVID-19 infection especially those with severe and critical infection remain at risk of VTE due to multiple factors including immobilisation, infection, respiratory failure, mechanical ventilation and central venous catheters. Abnormalities in coagulation including high D-dimers levels and procoagulant changes seem to be common and associated with poorer outcome. The frequency of VTE in our study was 11.2% (12 patients) with half of the patients developing pulmonary embolism. Four patients were diagnosed with VTE within 24 hours of admission, while the remaining eight patients developed VTE despite being on prophylactic anticoagulation. The rates of venous thromboembolism in patients with severe COVID-19 have been reported to range from 3.2% in non-ICU patients to 39% among ICU patients. A recent Dutch study found a 49% cumulative incidence of thrombotic complication among COVID-19 pneumonia patients in intensive care unit. Other studies have reported the incidence of thrombosis in around 20%-30% of the critically ill patients even with prophylaxis.

In a study in Milan, Italy, thromboembolic events occurred at a cumulative rate of 21% (27.6% of ICU, 6.6% general ward patients) with half of the
thromboembolic events diagnosed within 240.23 hours of hospital admission.

Few researchers have reported a low incidence of VTE in COVID-19 pneumonia patients. Cattaneo et al. reported no patient as having DVT in a study of non-ICU patients in Northern Italy. Other researchers have postulated that the incidence of VTE may have been overestimated in studies as immunothromboses associated with COVID-19 have been included as PE in these instances. However, VTE still remains a concern in patients with COVID-19 pneumonia as expected. Cui et al. for example, reported incidence of vascular thromboses of 5.9% in influenza H1N1.

The mean D-dimers in our study on first evaluation was high as expected (3322.24 ng/mL±9603 ng/mL) with one patient having D-dimer values in excess of 70,000 ng/mL. Patients with respiratory failure and those requiring ICU admission had a significantly higher mean values. Marked elevation of D-dimers has been a common finding in patients with COVID-19 requiring hospitalisation. Although high D-dimers levels are non-specific, it has consistently been reported as a poor prognostic marker in patients with COVID-19. Several studies have shown association of higher D-dimer values with mortality, reporting a higher D-dimer values in non-survivors compared with survivors.

In addition to being a marker of disease severity, higher D-dimer values have also been associated with high risk of VTE in patients with COVID-19 pneumonia as expected. Some authors have suggested anticoagulation therapy in patients with severe COVID-19 and higher D-dimers value over four times upper limit of normal. Others have suggested the need to adapt for anticoagulation in patients with COVID-19 as prophylactic anticoagulation does not avoid the occurrence of PE in these hospitalised patients. Importantly, significantly increased D-dimer is a good index for identifying high-risk groups of VTE. Cui et al. suggested that a cut-off value of 1500 ng/mL has a sensitivity of 85.0%, specificity 88.5% and the negative predictive value (NPV) of 94.7% for predicting VTE. In our study, all the patient with D-dimers value above 2000 ng/mL had confirmed VTE on imaging. This underscores the importance of keeping a low threshold for evaluating patients with high D-dimers value with dedicated imaging for excluding VTE in the right clinical scenario. The study further informs the readers of the real-life NHS hospital evidence of coagulopathy in patients with COVID-19 patients and also helps in establishing a cut-off value for D-dimers in these patients, which will help in establishing appropriate diagnostic algorithms for VTE in these cases and their subsequent management.

The study had several limitations being a small scale; single-centre study and the fact that not all of the patients involved in the study including those with high D-dimers were evaluated by dedicated imaging. In addition, as the study is retrospective in nature, many patients did not undergo complete laboratory investigations including D-dimers. Despite this, we have demonstrated that VTE is common in patients with COVID-19 infection with an incidence of approximately 11% even in optimally anticoagulated patients and that a D-dimer value above 2000 ng/mL is correlated well with radiological confirmation of VTE. We have also demonstrated that significantly elevated D-dimer values are associated with the requirement for intensive care. Therefore, the authors recommend that a D-dimer needs to be done on admission for all patients with COVID-19 and a result of more than 2000 ng/mL should lead to a consideration of appropriate imaging to exclude VTE.

Further large-scale studies will help in understanding the true incidence and significance of VTE and the optimal investigation algorithms in these patients.

**Contributors** MZX and VJ contributed equally to this paper and were involved in idea, data collection, data analysis, results compilation, drafting the work and final

---

### Table 4 Imaging results for VTE and correlation with D-dimers and anticoagulation protocol

<table>
<thead>
<tr>
<th>Imaging results for VTE</th>
<th>No imaging done</th>
<th>VTE on imaging</th>
<th>No VTE on imaging</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>No anticoagulation</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>Suboptimal prophylactic</td>
<td>8</td>
<td>0</td>
<td>1</td>
<td>9</td>
</tr>
<tr>
<td>Optimal prophylactic</td>
<td>60</td>
<td>8</td>
<td>8</td>
<td>76</td>
</tr>
<tr>
<td>Therapeutic dose</td>
<td>0</td>
<td>4</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>On regular DOACs/warfarin</td>
<td>13</td>
<td>0</td>
<td>1</td>
<td>14</td>
</tr>
<tr>
<td>Total</td>
<td>84</td>
<td>12</td>
<td>11</td>
<td>107</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>VTE frequency based on D-dimers cut-off of &gt;2000</th>
<th>D-dimers &lt;2000</th>
<th>D-dimers &gt;2000</th>
<th>No D-dimers available</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>No imaging done</td>
<td>40</td>
<td>2</td>
<td>9</td>
<td>51</td>
</tr>
<tr>
<td>VTE on imaging</td>
<td>14</td>
<td>7</td>
<td>0</td>
<td>21</td>
</tr>
<tr>
<td>No VTE on imaging</td>
<td>30</td>
<td>3</td>
<td>2</td>
<td>35</td>
</tr>
<tr>
<td>Total</td>
<td>84</td>
<td>12</td>
<td>11</td>
<td>107</td>
</tr>
</tbody>
</table>

DOACS, direct oral anticoagulants; ICU, intensive care unit; VTE, venous thromboembolism.
approval of the version. BS and FR contributed to design of the work, data analysis, critical revision for important intellectual content and final approval of the version. All four authors agree to be accountable for all aspects of the work in relation to accuracy and integrity of the work.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Muhammad Ziaullah Khan http://orcid.org/0000-0002-1530-3827

REFERENCES


